Home > Investors
Investor Relations Home
E-mail Page Print Page RSS Feeds E-mail Alerts IR Contacts Financial Tear Sheet 
About Us
Webcast ImageWebcast - Replay
Q2 2014 The Medicines Company Earnings Conference Call
07/23/14 at 8:30 a.m. ET
Corporate Profile
The Medicines Company provides medical solutions to improve health outcomes for patients in acute and intensive care hospitals worldwide. These solutions comprise medicines and knowledge that directly impact the survival and well-being of critically ill patients.
Stock Quote
MDCO (Common Stock)
ExchangeNASDAQ (US Dollar)
Change (%) Stock is Down 0.2 (0.81%)
Data as of 07/25/14 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent News
07/23/14The Medicines Company Reports Second Quarter and First Half 2014 Results
Second Quarter Net Revenues Rise 6%, First Half Net Revenues Rise 10%; Company continues year-over-year growth in revenue Company Reports Progress of Four Regulatory Applications for US and Europe R&D Portfolio Progress PARSIPPANY, N.J.--(BUSINESS WIRE)--Jul. 23, 2014-- The Medicines Company (NASDAQ:MDCO), a global company focused on saving lives, alleviating suffering, and contributing to the economics of healthcare by ... 
Printer Friendly Version
07/09/14The Medicines Company to Announce Second Quarter and First Half 2014 Financial Results on Wednesday, July 23, 2014
Conference Call to be held at 8:30 a.m. Eastern Time PARSIPPANY, N.J.--(BUSINESS WIRE)--Jul. 9, 2014-- The Medicines Company (NASDAQ: MDCO) has scheduled its quarterly conference call for Wednesday, July 23 at 8:30 a.m. Eastern Time to discuss second quarter and first half 2014 financial results, operational developments, and outlook for 2014. The conference call will be available via phone and webcast. The dial-in information is liste... 
Printer Friendly Version
07/07/14The Medicines Company Receives Market Authorization Renewal for Angiox® (Bivalirudin) from the European Medicines Agency and the European Commission
PARSIPPANY, N.J.--(BUSINESS WIRE)--Jul. 7, 2014-- The Medicines Company (NASDAQ:MDCO) today announced that the European Medicines Agency (EMA), the Committee for Medicinal Products for Human Use (CHMP), and the European Commission have granted market authorization renewal for Angiox® (bivalirudin) following a review of the latest clinical, safety, and efficacy data, as well as the Angiox risk management plan. The CHMP recommendation for the renewal of th... 
Printer Friendly Version
06/05/14ORBACTIVTM (Oritavancin) Phase 3 Trial Results Published in New England Journal of Medicine
SOLO I Trial studied single-dose ORBACTIVTM (oritavancin) in the treatment of acute bacterial skin and skin structure infections caused by Gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA) PARSIPPANY, N.J.--(BUSINESS WIRE)--Jun. 5, 2014-- The Medicines Company (NASDAQ:MDCO) today announced the publication of the results from the SOLO I Phase 3 clinical trial of ORBACTIVTM (oritavancin), an investigational intr... 
Printer Friendly Version
Upcoming Events
There are currently no events scheduled.

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.